Dermapharm Holding SE annual operating income
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Dermapharm Holding SE Operating Income Growth & History (DMP)
Dermapharm Holding SE's operating income was €220.7M for fiscal 2025.
View full Dermapharm Holding SE company overviewDermapharm Holding SE annual operating income history
| Fiscal year | Period ended | Operating income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €220.7M | €3.7M | +1.72% |
| 2024 | 2024-12-31 | €216.9M | €34.0M | +18.61% |
| 2023 | 2023-12-31 | €182.9M | −€60.8M | −24.95% |
| 2022 | 2022-12-31 | €243.7M | −€54.8M | −18.35% |
| 2021 | 2021-12-31 | €298.5M | €161.6M | +118.10% |
| 2020 | 2020-12-31 | €136.8M | €17.3M | +14.51% |
| 2019 | 2019-12-31 | €119.5M | €12.0M | +11.16% |
| 2018 | 2018-12-31 | €107.5M | €15.4M | +16.71% |
| 2017 | 2017-12-31 | €92.1M | €5.3M | +6.14% |
| 2016 | 2016-12-31 | €86.8M | €26.0M | +42.84% |
| 2015 | 2015-12-31 | €60.8M | €17.5M | +40.45% |
| 2014 | 2014-12-31 | €43.3M | — | — |
Dermapharm Holding SE quarterly operating income
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | €71.0M | €26.6M | +59.71% |
| Q1 2026 | 2026-03-31 | €70.7M | €10.9M | +18.19% |
| Q4 2025 | 2025-12-31 | €58.2M | — | — |
| Q3 2025 | 2025-09-30 | €64.9M | — | — |
| Q2 2025 | 2025-06-30 | €44.5M | — | — |
| Q1 2025 | 2025-03-31 | €59.8M | — | — |
Dermapharm Holding SE operating income trends
Over the last five fiscal years, Dermapharm Holding SE's operating income increased from €136.8M to €220.7M, a change of €83.8M. The latest reported quarter, Q2 2026, shows €71.0M.
About the metric
What operating income means
Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.
Calculation and source
reported operating income
TickerStat standardizes operating income reported in company official filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Dermapharm Holding SE source filings ↗